Cisplatin hearing loss data
http://mdedge.ma1.medscape.com/fedprac/article/227870/oncology/improving-ototoxicity-monitoring-cisplatin-therapy-va-northeast-ohio WebSep 1, 2024 · Improving Ototoxicity Monitoring with Cisplatin Therapy at VA Northeast Ohio Healthcare System (VANOHS), An Interdisciplinary Team Approach. Publish date: September 1, 2024. Author(s): Lisa Arfons, MD Yasmine Ayoub, PharmD, BCPS Deborah Fox, RN, BSN, MSHS Jill Lagerstedt, MA, CCC-A, Clinical Audiologist
Cisplatin hearing loss data
Did you know?
WebFeb 15, 2024 · Overall, the study showed that 44% of pediatric patients treated with cisplatin suffered from moderate to severe hearing loss. But the data showed that not … WebCisplatin-induced early-onset ototoxicity is linked to hearing loss. The mechanism by which cisplatin causes ototoxicity remains unclear. The purpose of this study was to …
WebDec 11, 2024 · It is used for the treatment of a variety of cancers such as cervical, breast, stomach, prostate, bladder and oesophageal, to name a few. However due to its expansive toxicity profile, patients receiving cisplatin can experience high frequency hearing loss, a side effect known as ototoxicity. WebFeb 28, 2024 · One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anticancer complexes. In …
WebSigns and symptoms seen in children as ototoxicity develops include: High-frequency (≥4 kHz) sensorineural hearing loss that is bilateral (affecting both sides), progressive, and … WebTaking a genome-wide association study approach, we identified inherited genetic variations in ACYP2 associated with cisplatin-related ototoxicity (rs1872328: P = 3.9 × 10(-8), hazard ratio = 4.5) in 238 children with newly diagnosed brain tumors,
WebJan 1, 2024 · The benefits of atorvastatin to the incidence of a CTCAE-defined hearing loss were generally consistent across all subgroups (Figure 3). Overall, 48.8% (156 of 320) of …
WebCisplatin is an effective chemotherapeutic agent against pediatric cancers; however, ototoxicity is a concern. This study describes the frequency, severity, and clinical course … green school for girls addressWebModern research on ototoxicity goes back to the 1940s, when streptomycin was introduced into clinical practice. Today, aminoglycoside antibiotics and platinum-based chemotherapy, mainly cisplatin, are the most important drugs that … fmh partsWebAfter the first cycle of cisplatin, in the placebo ears, 76% of patients experienced hearing loss in the clinical frequency range that met the ototoxicity criteria established by the American Speech-Language-Hearing Association. f.m. howell \u0026 coWebJul 13, 2024 · Hearing loss can have significant long-term consequences for children treated for cancer, said Edward Neuwelt, M.D., of Oregon Health & Science University, who helped lead both recent trials. “Around 60% to … green school for girls walthamstowWebNov 21, 2024 · Cisplatin chemotherapy causes permanent hearing loss in 40–80% of treated patients. It is unclear whether the cochlea has unique sensitivity to cisplatin or is … green school korea universityWebSep 21, 2016 · Individually, children in this series first showed decreases in hearing after cumulative cisplatin doses ranging between 75 and 600 mg/m 2 and carboplatin doses between 800 and 3,420 mg/m 2. Patients treated for germ cell tumors (Children's Oncology Group 8882) received the highest cumulative doses of cisplatin. green school isleworth for girlsWebApr 6, 2016 · Significance statement: Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumors. Its use results in significant and permanent hearing loss, for which no US Food and Drug Administration-approved treatment is currently available. green school in bali is an unusual school